Last update on 10 November 2026
Current Pompe delays: Due to low inventory globally, we are experiencing batch-release and distribution process delays for our Pompe disease medicines in some countries. These may temporarily affect product availability.
What we are doing for Pompe: We are working closely with local teams to minimize disruption for patients currently receiving enzyme replacement therapies and support access for those with urgent medical need, within each country’s regulatory framework. We have made progress toward restoring consistent supply, including importing product to many countries that have experienced treatment interruptions. We cannot yet provide a single global date for full restoration because circumstances vary by product and country. We will continue to keep patients, healthcare providers and regulatory authorities informed through country-specific updates as supply availability and local conditions evolve.
Current Xenpozyme delays: As of November 2026, we anticipate a shortage in some countries of Xenpozyme® (olipudase alfa) 4 mg and 20 mg, for the treatment of non‑central nervous system (non‑CNS) manifestations of acid sphingomyelinase deficiency (ASMD). Previous manufacturing limitations depleted inventory, and despite operating at maximum capacity, output has not kept pace with increased demand. We are working quickly and diligently to manage global supply and minimize the impact on patients living with ASMD as much as possible.
Looking ahead, Xenpozyme forecast: Separate from the current delays, our current forecasts and anticipated consumption, Sanofi expects that global supply of Xenpozyme will become insufficient to meet demand beginning in mid-2027. Xenpozyme is approved in many countries and is currently the only approved treatment for ASMD worldwide.
Why this is happening: Xenpozyme is a complex biologic medicine that requires a specialized manufacturing process. The forecasted shortage is due to factors including lower-than-planned production during an earlier period, which reduced available inventory; the time required to expand manufacturing capacity; and continued growth in the number of patients receiving treatment.
What we are doing: We are working to increase long-term production capacity, but because that capacity will take time to bring online, interim measures are needed to manage available supply and reduce the risk of a global shortage. We are acting now to develop potential approaches intended to minimize impact and help preserve access to treatment for as many patients as possible.
Product safety, all medicines: All medicines released continue to meet all established requirements for identity, strength, quality and purity.
Next steps: We are focused on minimizing disruptions across all our therapies. We recognize the disruption these shortages have on patients and their families, and we will continue to provide timely updates as each situation evolves.
For treatment questions: Healthcare professionals with questions about product supply should contact their Sanofi representative. Patients who have questions about their treatments or infusions should contact their doctor or healthcare team.
_____________________________________________________
Last update on 26 October 2026
Sanofi is experiencing shipping delays for its Pompe disease medicines in some countries. Due to low global inventory, delays in batch release and distribution may temporarily affect product availability. These delays may last several weeks and may lead to treatment interruptions. Every batch released continues to meet all established requirements for identity, strength, quality and purity.
Supply interruptions also continue to affect Sanofi's enzyme replacement therapies for ASMD, Fabry and Gaucher in some countries. Sanofi has made progress toward restoring consistent supply, including importing product to many countries that have experienced treatment interruptions.
We cannot yet provide a single global date for full restoration because circumstances vary by product and country. We are working closely with local teams to minimize disruption for patients currently receiving treatment and to support access for those with urgent medical need, within each country's regulatory framework. We will continue to keep patients, healthcare providers and regulatory authorities informed through country-specific updates as supply availability and local conditions evolve.
Continuity of care remains our highest priority. Healthcare providers with questions about product availability should contact their local Sanofi representative. Patients or family members affected by a delay are encouraged to contact their doctor or healthcare team for guidance based on their individual medical needs.